Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Completed
Bayer
Phase 3
2015-09-17
The primary objective of this study was to demonstrate whether, in addition to standard of
care, finerenone is superior to placebo in delaying the progression of kidney disease, as
measured by the composite endpoint of time to first occurrence of kidney failure, a sustained
decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4
weeks, or renal death.
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Completed
Bayer
Phase 3
2015-09-17
The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to
standard daily therapy, is effective and safe in treating patients with type 2 diabetes
mellitus and diabetic kidney disease, when compared to a placebo.
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers
Completed
Bayer
Phase 1
2016-11-16
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic
kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics
of a single oral dose of finerenone (1.25 mg tablet and 5 x 0.25 mg tablets) using a novel
orodispersible tablet formulation for the treatment of children, in comparison to the adult
tablet formulation.
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects
Completed
Bayer
Phase 1
2016-11-17
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic
kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics
of a novel liquid formulation for the treatment of children in comparison to the adult tablet
formulation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
